| Name | Title | Contact Details |
|---|
Meyers Brothers Kalicka, P.C. is the largest independently owned and operated CPA firm based in Western Massachusetts. Our services go beyond accounting, auditing, taxation and financial planning to include proactive business strategy. With offices in Holyoke, we serve clients throughout the Pioneer Valley, including Springfield, West Springfield, Chicopee, Holyoke, Northampton, Amherst, Greenfield, Pittsfield and beyond. Our roots are in Western Massachusetts and we have a passion for the businesses, organizations and people of our region. We are approachable, accessible and dedicated to helping you reach your financial and business goals.
We are an Enterprise Transformation Digital Technology Consulting company. Our team is made up of Professional Consultants who have led Enterprise Transformations, Project Management Offices, CIO, CAO, CTO, CHRO, COO, Global ERP Directors, ERP Business Systems Analysts, ERP Developers, CyberSecurity Analysts. This gives us a unique perspective, allowing us to understand our clients visions, appreciating the right balance of consulting to work. We have a proven track record of helping our clients achieve their vision with the optimization of Digital solutions, so we guarantee our work. Services: - Strategy to Execution OKRs (Workboard) - Enterprise Performance Management (EPM) - Enterprise Resource Planning (ERP) - Customer Excellence Solutions (CRM) - Supply Chain Excellence Solutions - Backoffice Excellence Solutions (BPM RPA) - Employee Excellence Solutions (HCM) - Cloud & Managed Services - IT Advisory - Mergers & Acquisitions - Project Management - CyberSecurity Industries: - Engineering, Procurement, Construction (EPC) - Industrial Manufacturing/Fabrication - Oil & Gas. Chemical, Nuclear, Solar, and Power Industries *Ask about our OneVision Consulting Network on our Contact Us Page for more information on how to apply.*
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.